Sanofi sharp­ens fo­cus on bis­pecifics, and Chi­na, with Al­pham­ab deal

It’s not the splashy ac­qui­si­tion Sanofi was ex­pect­ed to make af­ter pock­et­ing more than $11 bil­lion fol­low­ing the sale of a big chunk of part­ner Re­gen­eron’s stock, but it’s a start. On Tues­day, the com­pa­ny signed a pact with Chi­na’s Al­pham­ab On­col­o­gy to col­lab­o­rate on a bis­pe­cif­ic an­ti­body fo­cused on treat­ing breast can­cer.

The deal rep­re­sents Sanofi’s am­bi­tions in Chi­na, where sky­rock­et­ing rates of can­cer have sparked the cre­ation of biotech firms that have lured mil­lions in ven­ture fund­ing and pub­lic list­ings.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.